Symbols / CORT Stock $75.22 +3.54% Corcept Therapeutics Incorporated

Healthcare • Biotechnology • United States • NCM
CORT (Stock) Chart
O: — H: — L: — C: — V: —
SMA 20: — SMA 50: — SMA 200: —
Stock Fundamentals
Scroll to Statements
Index EQUITY
Sector Healthcare
Industry Biotechnology
CEO Dr. Joseph K. Belanoff M.D.
Exch · Country NCM · United States
Market Cap 8.07B
Enterprise Value 7.47B
Income 46.68M
Sales 769.10M
FCF (ttm) 115.66M
Book/sh 5.94
Cash/sh 3.15
Employees 730
Insider 10d —
IPO Apr 14, 2004
Div forward ($/yr)
Div TTM ($/yr)
Dividend Yield
Ex-Div Date
5Y Avg Yield
Yield vs 5Y Avg
Payout 0.00%
P/E 214.91
Forward P/E 30.15
PEG 0.81
P/S 10.50
P/B 12.65
P/C —
EV/EBITDA -1,077.22
EV/Sales 9.71
Quick Ratio 2.53
Current Ratio 2.86
Debt/Eq 1.51
LT Debt/Eq —
EPS (ttm) 0.35
EPS next Y 2.50
EPS Growth —
Revenue Growth 4.90%
EPS Gr Q/Q —
Rev Gr Q/Q —
Earnings (next) 2026-07-30
Earnings (prior) 2026-04-30
ROA -0.62%
ROE 7.17%
ROIC —
Gross Margin 98.25%
Oper. Margin -30.08%
Profit Margin 6.16%
Shs Outstand 107.35M
Shs Float 88.99M
Insider Own 11.54%
Instit Own 75.76%
Short Float 11.20%
Short Ratio 7.72
Short Interest 9.32M
52W High 91.00
vs 52W High -17.34%
52W Low 28.66
vs 52W Low 162.46%
Beta 0.35
Impl. Vol. 65.03%
Rel Volume 0.18
Avg Volume 1.42M
Volume 262.79K
Target (mean) $88.00
Tgt Median $88.00
Tgt Low $50.00
Tgt High $135.00
# Analysts 5
Recom Strong_buy
Prev Close $72.65
Price $75.22
Change 3.54%
About

Corcept Therapeutics Incorporated, a biopharmaceutical company, engages in the discovery and development of medications to treat severe endocrinologic, oncologic, metabolic, and neurologic disorders in the United States. The company offers Korlym, an oral medication for the treatment of hyperglycemia secondary to hypercortisolism in adult patients with endogenous Cushing's syndrome who have type 2 diabetes mellitus or glucose intolerance and have failed surgery or are not candidates for surgery. It also develops relacorilant, a selective cortisol modulator for patients with hypercortisolism; a selective cortisol modulator miricorilant, which is in Phase 1b trial for metabolic dysfunction-associated steatohepatitis; and a portfolio of proprietary selective cortisol modulators, such as relacorilant, nenocorilant, miricorilant, and dazucorilant for the treatment of Lou Gehrig's disease. The company was incorporated in 1998 and is headquartered in Redwood City, California.

Valuation Models

Price estimates from analyst targets and simple models.

1. Analyst consensus
$88.00
Mean price target
2. Current target
$75.22
Latest analyst target
3. DCF / Fair value
$19.39
Simplified: (Free Cash Flow ÷ Shares) × 18 (P/FCF multiple). Not a …
Ratings
Current target
$75.22
Low
$50.00
High
$135.00
Mean
$88.00

Latest analyst rating changes

Date Action Analyst Rating Change Price Target
2026-05-28 main Canaccord Genuity Buy → Buy $135
2026-05-28 main HC Wainwright & Co. Buy → Buy $95
2026-05-13 up UBS Neutral → Buy $72
2026-05-04 main HC Wainwright & Co. Buy → Buy $75
2026-05-01 main Piper Sandler Overweight → Overweight $88
2026-03-26 main Canaccord Genuity Buy → Buy $110
2026-03-26 up Wolfe Research Underperform → Peer Perform —
2026-03-25 main HC Wainwright & Co. Buy → Buy $60
2026-02-25 main HC Wainwright & Co. Buy → Buy $60
2026-02-20 main HC Wainwright & Co. Buy → Buy $67
2026-01-23 main Canaccord Genuity Buy → Buy $100
2026-01-23 main HC Wainwright & Co. Buy → Buy $105
2026-01-02 main Canaccord Genuity Buy → Buy $99
2026-01-02 main HC Wainwright & Co. Buy → Buy $90
2025-12-16 init UBS — → Neutral $95
2025-11-25 reit HC Wainwright & Co. Buy → Buy $145
2025-11-18 init Wolfe Research — → Peer Perform —
2025-10-20 reit HC Wainwright & Co. Buy → Buy $145
2025-10-10 reit HC Wainwright & Co. Buy → Buy $145
2025-09-25 main Canaccord Genuity Buy → Buy $140
News
RSS: Latest CORT news
Insider Transactions
Filed Date Insider Relationship Transaction Shares Price Value SEC
2026-06-01 MOKARI ATABAK Chief Financial Officer — 40,000 $19.26 $770,400
2026-06-01 MADUCK SEAN Officer — 25,000 $8.27 $206,750
2026-06-01 MOKARI ATABAK Chief Financial Officer — 40,000 $70.00 $2,800,004
2026-06-01 MADUCK SEAN Officer — 25,000 $70.11 $1,755,183
2026-06-01 BELANOFF JOSEPH K Chief Executive Officer — 12,837 $69.74 $895,252
2026-06-01 MOKARI ATABAK Chief Financial Officer — 1,268 $0.00 $44,659
2026-06-01 MADUCK SEAN Officer — 1,230 $0.00 $43,321
2026-05-29 BELANOFF JOSEPH K Chief Executive Officer — 300,000 $0.00 $0
2026-05-27 WILSON JAMES N Director — 901,067 $0.00 $0
2026-05-27 MADUCK SEAN Officer — 75,000 $8.27 $620,250
Financials
Statement View
Amounts in millions (2 decimals, no suffix) • EPS per share (2 decimals) • Trend = period evolution • YoY Growth = previous period %
Line Item Trend 2025-12-31 2024-12-31 2023-12-31 2022-12-31
Total Revenue
761.41
+12.79%
675.04
+39.94%
482.38
+20.04%
401.86
Operating Revenue
761.41
+12.79%
675.04
+39.94%
482.38
+20.04%
401.86
Cost Of Revenue
12.98
+19.25%
10.88
+67.91%
6.48
+20.35%
5.38
Reconciled Cost Of Revenue
12.98
+19.25%
10.88
+67.91%
6.48
+20.35%
5.38
Gross Profit
748.43
+12.69%
664.16
+39.56%
475.89
+20.03%
396.47
Operating Expense
703.63
+33.46%
527.21
+43.02%
368.61
+29.87%
283.84
Research And Development
254.91
+3.25%
246.89
+33.92%
184.35
+40.74%
130.99
Selling General And Administration
448.73
+60.08%
280.32
+52.13%
184.26
+20.55%
152.85
Total Expenses
716.61
+33.18%
538.09
+43.45%
375.09
+29.69%
289.22
Operating Income
44.80
-67.29%
136.95
+27.66%
107.28
-4.75%
112.63
Total Operating Income As Reported
44.80
-67.29%
136.95
+27.66%
107.28
-4.75%
112.63
EBITDA
—
—
—
116.08
Normalized EBITDA
46.69
-66.24%
138.29
+26.12%
109.64
-5.54%
116.08
Reconciled Depreciation
1.89
+41.47%
1.34
-43.44%
2.36
-31.46%
3.45
EBIT
44.80
-67.29%
136.95
+27.66%
107.28
-4.75%
112.63
Total Unusual Items
—
0.00
0.00
0.00
Total Unusual Items Excluding Goodwill
—
0.00
0.00
0.00
Special Income Charges
—
0.00
0.00
0.00
Net Income
99.65
-29.43%
141.21
+33.04%
106.14
+4.66%
101.42
Pretax Income
66.46
-58.84%
161.49
+29.65%
124.56
+7.20%
116.19
Net Non Operating Interest Income Expense
21.67
-11.72%
24.54
+42.07%
17.27
+385.66%
3.56
Net Interest Income
21.67
-11.72%
24.54
+42.07%
17.27
+385.66%
3.56
Interest Income Non Operating
21.67
-11.72%
24.54
+42.07%
17.27
+385.66%
3.56
Interest Income
21.67
-11.72%
24.54
+42.07%
17.27
+385.66%
3.56
Tax Provision
-33.19
-263.62%
20.28
+10.14%
18.42
+24.67%
14.77
Tax Rate For Calcs
0.00
+67.19%
0.00
-15.05%
0.00
+16.29%
0.00
Tax Effect Of Unusual Items
0.00
0.00
0.00
0.00
Net Income Including Noncontrolling Interests
99.65
-29.43%
141.21
+33.04%
106.14
+4.66%
101.42
Net Income From Continuing Operation Net Minority Interest
99.65
-29.43%
141.21
+33.04%
106.14
+4.66%
101.42
Net Income From Continuing And Discontinued Operation
99.65
-29.43%
141.21
+33.04%
106.14
+4.66%
101.42
Net Income Continuous Operations
99.65
-29.43%
141.21
+33.04%
106.14
+4.66%
101.42
Normalized Income
99.65
-29.43%
141.21
+33.04%
106.14
+4.66%
101.42
Net Income Common Stockholders
98.17
-29.74%
139.73
+32.45%
105.50
+4.15%
101.29
Otherunder Preferred Stock Dividend
1.48
+0.34%
1.48
+129.19%
0.64
+395.38%
0.13
Diluted EPS
0.82
-33.33%
1.23
+30.85%
0.94
+8.05%
0.87
Basic EPS
0.95
-29.63%
1.35
+32.35%
1.02
+7.37%
0.95
Basic Average Shares
103.86
+0.61%
103.23
-0.32%
103.56
-3.02%
106.79
Diluted Average Shares
119.99
+5.73%
113.48
+1.56%
111.74
-3.64%
115.97
Diluted NI Availto Com Stockholders
98.17
-29.74%
139.73
+32.45%
105.50
+4.15%
101.29
Line Item Trend 2025-12-31 2024-12-31 2023-12-31 2022-12-31
Total Assets
836.65
-0.46%
840.55
+35.24%
621.52
+6.53%
583.43
Current Assets
485.46
+2.94%
471.60
+2.83%
458.64
-8.14%
499.25
Cash Cash Equivalents And Short Term Investments
372.15
-2.92%
383.33
+4.10%
368.22
-14.70%
431.67
Cash And Cash Equivalents
120.50
-5.62%
127.67
-5.82%
135.55
+104.36%
66.33
Other Short Term Investments
251.66
-1.57%
255.67
+9.88%
232.67
-36.31%
365.34
Receivables
59.79
+10.76%
53.98
-2.08%
55.12
+22.34%
45.06
Accounts Receivable
59.79
+10.76%
53.98
+31.26%
41.12
+32.41%
31.06
Other Receivables
—
—
14.00
+0.00%
14.00
Inventory
12.87
+3.67%
12.41
+60.57%
7.73
+26.72%
6.10
Raw Materials
0.85
0.00
—
—
Work In Process
13.70
+75.93%
7.79
-5.39%
8.23
+5.19%
7.83
Finished Goods
9.41
+14.70%
8.21
+6.01%
7.74
-15.90%
9.20
Prepaid Assets
28.50
+151.97%
11.31
+38.18%
8.18
—
Current Deferred Assets
5.06
+12.64%
4.49
-66.71%
13.50
—
Other Current Assets
7.10
+16.85%
6.08
+3.33%
5.88
-64.19%
16.42
Total Non Current Assets
351.19
-4.81%
368.95
+126.52%
162.88
+93.50%
84.18
Net PPE
6.47
-19.22%
8.01
+2443.81%
0.32
-82.26%
1.78
Gross PPE
6.47
-19.22%
8.01
+2443.81%
0.32
-82.26%
1.78
Accumulated Depreciation
—
—
—
-3.71
Properties
—
—
—
0.00
Machinery Furniture Equipment
—
—
—
2.74
Other Properties
6.47
-19.22%
8.01
+2443.81%
0.32
-82.26%
1.78
Leases
—
—
—
1.60
Investments And Advances
160.27
-27.09%
219.83
+284.48%
57.18
+1055.77%
4.95
Non Current Deferred Assets
168.20
+28.48%
130.91
+44.49%
90.61
+47.41%
61.47
Non Current Deferred Taxes Assets
168.20
+28.48%
130.91
+44.49%
90.61
+47.41%
61.47
Other Non Current Assets
16.25
+59.39%
10.19
-31.06%
14.79
-7.53%
15.99
Total Liabilities Net Minority Interest
188.85
+17.32%
160.96
+40.20%
114.81
+40.72%
81.59
Current Liabilities
166.09
+17.98%
140.77
+34.70%
104.50
+44.16%
72.49
Payables And Accrued Expenses
85.01
+61.65%
52.59
-12.02%
59.77
+35.93%
43.98
Payables
40.44
+163.03%
15.38
-24.21%
20.29
+68.16%
12.06
Accounts Payable
40.44
+163.03%
15.38
-11.61%
17.40
+45.26%
11.98
Current Accrued Expenses
44.56
+19.75%
37.21
-5.76%
39.49
+23.74%
31.91
Pensionand Other Post Retirement Benefit Plans Current
37.40
-10.38%
41.73
+63.93%
25.46
+64.12%
15.51
Total Tax Payable
—
0.19
-93.40%
2.89
+3149.44%
0.09
Income Tax Payable
—
0.19
-89.47%
1.81
+1938.20%
0.09
Current Debt And Capital Lease Obligation
1.08
+30.76%
0.83
+449.01%
0.15
-86.79%
1.14
Current Capital Lease Obligation
1.08
+30.76%
0.83
+449.01%
0.15
-86.79%
1.14
Current Deferred Liabilities
35.68
-14.19%
41.58
+125.15%
18.47
+66.41%
11.10
Current Deferred Revenue
35.68
-14.19%
41.58
+125.15%
18.47
+66.41%
11.10
Other Current Liabilities
6.91
+70.97%
4.04
+518.35%
0.65
-14.29%
0.76
Total Non Current Liabilities Net Minority Interest
22.76
+12.73%
20.19
+95.90%
10.31
+13.30%
9.10
Long Term Debt And Capital Lease Obligation
5.02
-17.75%
6.11
0.00
—
Long Term Capital Lease Obligation
5.02
-17.75%
6.11
0.00
—
Tradeand Other Payables Non Current
15.18
+7.75%
14.08
+36.64%
10.31
+13.30%
9.10
Stockholders Equity
647.80
-4.68%
679.59
+34.12%
506.70
+0.97%
501.84
Common Stock Equity
647.80
-4.68%
679.59
+34.12%
506.70
+0.97%
501.84
Capital Stock
0.14
+2.94%
0.14
+2.26%
0.13
+1.53%
0.13
Common Stock
0.14
+2.94%
0.14
+2.26%
0.13
+1.53%
0.13
Preferred Stock
0.00
0.00
0.00
0.00
Share Issued
142.52
+3.46%
137.75
+2.54%
134.34
+2.58%
130.96
Ordinary Shares Number
105.97
+0.81%
105.11
+1.65%
103.41
-4.11%
107.83
Treasury Shares Number
36.55
+11.99%
32.64
+5.50%
30.94
+33.80%
23.12
Additional Paid In Capital
968.60
+16.40%
832.11
+12.67%
738.51
+11.50%
662.34
Retained Earnings
643.39
+18.33%
543.74
+35.08%
402.53
+35.81%
296.39
Gains Losses Not Affecting Retained Earnings
2.26
+1143.32%
-0.22
-135.63%
0.61
+170.08%
-0.87
Treasury Stock
966.59
+38.84%
696.17
+9.62%
635.08
+39.23%
456.15
Other Equity Adjustments
2.26
+1143.32%
-0.22
-135.63%
0.61
+170.08%
-0.87
Total Equity Gross Minority Interest
647.80
-4.68%
679.59
+34.12%
506.70
+0.97%
501.84
Total Capitalization
647.80
-4.68%
679.59
+34.12%
506.70
+0.97%
501.84
Working Capital
319.38
-3.46%
330.83
-6.58%
354.13
-17.02%
426.76
Invested Capital
647.80
-4.68%
679.59
+34.12%
506.70
+0.97%
501.84
Total Debt
6.11
-11.95%
6.94
+4493.38%
0.15
-86.79%
1.14
Capital Lease Obligations
6.11
-11.95%
6.94
+4493.38%
0.15
-86.79%
1.14
Net Tangible Assets
647.80
-4.68%
679.59
+34.12%
506.70
+0.97%
501.84
Tangible Book Value
647.80
-4.68%
679.59
+34.12%
506.70
+0.97%
501.84
Available For Sale Securities
160.27
-27.09%
219.83
+284.48%
57.18
+1055.77%
4.95
Inventories Adjustments Allowances
-11.09
-209.63%
-3.58
+56.54%
-8.24
+24.58%
-10.93
Investmentin Financial Assets
160.27
-27.09%
219.83
+284.48%
57.18
+1055.77%
4.95
Non Current Accrued Expenses
2.56
0.00
—
—
Line Item Trend 2025-12-31 2024-12-31 2023-12-31 2022-12-31
Operating Cash Flow
142.00
-28.39%
198.29
+56.53%
126.68
+5.28%
120.32
Cash Flow From Continuing Operating Activities
142.00
-28.39%
198.29
+56.53%
126.68
+5.28%
120.32
Net Income From Continuing Operations
99.65
-29.43%
141.21
+33.04%
106.14
+4.66%
101.42
Depreciation Amortization Depletion
1.89
+41.47%
1.34
-43.44%
2.36
-31.46%
3.45
Depreciation
1.89
+41.47%
1.34
-43.44%
2.36
-31.46%
3.45
Amortization Cash Flow
—
—
0.47
-2.52%
0.48
Depreciation And Amortization
1.89
+41.47%
1.34
-43.44%
2.36
-31.46%
3.45
Amortization Of Intangibles
—
—
0.47
-2.52%
0.48
Other Non Cash Items
—
—
—
1.38
Stock Based Compensation
84.50
+37.73%
61.35
+25.37%
48.94
+15.31%
42.44
Deferred Tax
-37.54
+6.60%
-40.19
-36.27%
-29.49
+13.01%
-33.91
Deferred Income Tax
-37.54
+6.60%
-40.19
-36.27%
-29.49
+13.01%
-33.91
Change In Working Capital
-1.41
-103.09%
45.52
+479.20%
7.86
+41.90%
5.54
Change In Receivables
-5.81
-606.54%
1.15
+111.39%
-10.07
+42.26%
-17.43
Changes In Account Receivables
-5.81
+54.80%
-12.85
-27.69%
-10.07
-193.30%
-3.43
Change In Inventory
-7.48
-2552.79%
0.30
-75.89%
1.26
+5.50%
1.20
Change In Prepaid Assets
-18.92
-448.89%
5.42
+146.73%
-11.60
-76.96%
-6.56
Change In Payables And Accrued Expense
30.17
-21.70%
38.54
+24.17%
31.04
-4.51%
32.50
Change In Accrued Expense
4.01
-89.09%
36.78
+50.70%
24.41
+28.06%
19.06
Change In Payable
26.16
+1388.90%
1.76
-73.50%
6.63
-50.69%
13.45
Change In Account Payable
25.07
+1340.99%
-2.02
-137.27%
5.42
+13.94%
4.76
Change In Other Current Assets
1.46
+2211.59%
-0.07
+95.35%
-1.48
+24.91%
-1.98
Change In Other Current Liabilities
-0.83
-553.01%
0.18
+114.20%
-1.29
+41.38%
-2.20
Investing Cash Flow
69.76
+139.28%
-177.60
-295.37%
90.91
+179.51%
-114.33
Cash Flow From Continuing Investing Activities
69.76
+139.28%
-177.60
-295.37%
90.91
+179.51%
-114.33
Net PPE Purchase And Sale
-0.21
+90.29%
-2.17
-1462.59%
-0.14
+66.34%
-0.41
Purchase Of PPE
-0.21
+90.29%
-2.17
-1462.59%
-0.14
+66.34%
-0.41
Capital Expenditure
-0.21
+90.29%
-2.17
-1462.59%
-0.14
+66.34%
-0.41
Net Investment Purchase And Sale
69.97
+139.88%
-175.43
-292.69%
91.05
+179.92%
-113.91
Purchase Of Investment
-319.61
+45.67%
-588.31
-78.95%
-328.75
+7.41%
-355.07
Sale Of Investment
389.58
-5.64%
412.88
-1.65%
419.79
+74.08%
241.15
Financing Cash Flow
-220.37
-677.33%
-28.35
+80.94%
-148.72
-760.47%
-17.28
Cash Flow From Continuing Financing Activities
-220.37
-677.33%
-28.35
+80.94%
-148.72
-760.47%
-17.28
Net Common Stock Issuance
0.00
0.00
+100.00%
-145.43
0.00
Common Stock Payments
0.00
0.00
+100.00%
-145.43
0.00
Repurchase Of Capital Stock
0.00
0.00
+100.00%
-145.43
0.00
Proceeds From Stock Option Exercised
-147.43
-2337.58%
-6.05
-204.08%
5.81
+32.64%
4.38
Net Other Financing Charges
-72.94
-227.08%
-22.30
-144.90%
-9.11
+57.97%
-21.66
Changes In Cash
-8.61
-12.46%
-7.66
-111.12%
68.86
+710.06%
-11.29
Effect Of Exchange Rate Changes
1.44
+732.46%
-0.23
-163.69%
0.36
—
Beginning Cash Position
127.67
-5.82%
135.55
+104.36%
66.33
-14.54%
77.62
End Cash Position
120.50
-5.62%
127.67
-5.82%
135.55
+104.36%
66.33
Free Cash Flow
141.78
-27.71%
196.12
+54.99%
126.54
+5.53%
119.91
Income Tax Paid Supplemental Data
12.97
-78.48%
60.27
+26.61%
47.60
+19.76%
39.75
Amortization Of Securities
-5.10
+53.35%
-10.94
-19.83%
-9.13
-760.01%
1.38
Change In Income Tax Payable
1.09
-71.09%
3.78
+212.15%
1.21
-86.07%
8.69
Change In Tax Payable
1.09
-71.09%
3.78
+212.15%
1.21
-86.07%
8.69
SEC Filings

Recent 10-K, 10-Q, 8-K, and Form 4 (insider) filings.

Trades
Date User Broker Pattern Type Position Size Entry Price Trade P&L Status
Posts
Published Title Author Category